Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| American Oncology Network, Inc.AONC · Entity 88884 | Director | July 16, 2024 | July 18, 2024 |
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director | May 14, 2026 | May 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
American Oncology Network, Inc.
Report date July 16, 2024 · Filed July 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 19,981 |
Reported balance
After 2024-07-16 transaction · row 1
1 source rowRow 1 · 2024-07-16 · Grant · Acquired 5,000 · Balance 19,981 F1: 5,000 shares of Class A Common Stock granted for service as an independent director on the American Oncology Network, Inc. Board of Directors. 3,250 shares will vest on a time-based vesting schedule over four years and 1,750 shares will vest based on a performance-based vesting schedule. |
Filing footnotes · ownership attribution and instrument terms
F1: 5,000 shares of Class A Common Stock granted for service as an independent director on the American Oncology Network, Inc. Board of Directors. 3,250 shares will vest on a time-based vesting schedule over four years and 1,750 shares will vest based on a performance-based vesting schedule.
TriSalus Life Sciences, Inc.
Report date May 14, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,241 |
Ending reported balance
After 2026-05-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-14 · Grant · Acquired 28,201 · Balance 58,688 F1: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Row 2 · 2026-05-14 · Grant · Acquired 24,553 · Balance 83,241 F2: Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2036-05-13 | Direct | 112,653 |
Reported balance
After 2026-05-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-14 · Grant · Acquired 56,403 · Balance 112,653 F3: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.
F2: Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer.
F3: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 15, 2026 20:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 56,403 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001628280-26-035663 · wk-form4_1778877546.xml · derivative · entry 3 Valle William · CIK 0002018493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,653 Underlying: Common Stock · 56,403 shares Expires 2036-05-13 F3 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 24,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-035663 · wk-form4_1778877546.xml · nonDerivative · entry 2 Valle William · CIK 0002018493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,241 F2 · shares: Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 14, 2026 Filed May 15, 2026 20:39 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantCommon Stock | 28,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-035663 · wk-form4_1778877546.xml · nonDerivative · entry 1 Valle William · CIK 0002018493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,688 F1 · shares: Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 23, 2026 Filed Feb 23, 2026 21:08 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | PurchaseCommon Stock | 30,487 | $4.10 | $124,996.70 |
DisclosureSEC source: 0001628280-26-010604 · wk-form4_1771880892.xml · nonDerivative · entry 1 Valle William · CIK 0002018493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,487 Read SEC document |
| June 12, 2025 Filed Jun 27, 2025 20:16 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001826667-25-000081 · wk-form4_1751055368.xml · derivative · entry 1 Valle William · CIK 0002018493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Stock · 15,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of June 12, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:00 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001415889-25-002541 · form4-01312025_110103.xml · derivative · entry 2 Valle William · CIK 0002018493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2035-01-28 F2 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of January 29, 2025, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 23:00 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001415889-25-002541 · form4-01312025_110103.xml · derivative · entry 1 Valle William · CIK 0002018493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-01-28 F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of January 29, 2025, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 20:47 UTC | American Oncology Network, Inc. AONC · Entity 88884 | GrantClass A Common Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001839998-24-000074 · wk-form4_1721335624.xml · nonDerivative · entry 1 Valle William · CIK 0002018493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,981 F1 · shares: 5,000 shares of Class A Common Stock granted for service as an independent director on the American Oncology Network, Inc. Board of Directors. 3,250 shares will vest on a time-based vesting schedule over four years and 1,750 shares will vest based on a performance-based vesting schedule. Read SEC document |
| May 04, 2024 Filed May 7, 2024 17:26 UTC | American Oncology Network, Inc. AONC · Entity 88884 | GrantClass A Common Stock | 14,981 | $0.00 | $0.00 |
DisclosureSEC source: 0001839998-24-000034 · wk-form4_1715102755.xml · nonDerivative · entry 1 Valle William · CIK 0002018493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,981 F1 · shares: 14,981 shares of Class A Common Stock granted for service as an independent director on the American Oncology Network, Inc. Board of Directors, all of which will vest on May 4, 2025 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.